YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.87 USD
-0.74 (-5.44%)
Updated May 9, 2024 04:00 PM ET
After-Market: $12.84 -0.03 (-0.23%) 5:02 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 41 - 60 ( 147 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Danyelza Adoption Picking Up; Progress on All Fronts
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chief Executive''s Departure Leaves Our Outlook Unchanged; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 1Q22 Revenue and Guidance In-line; CEO Transition
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chinese NMPA Accepts DANYELZA HITS Regimen IND; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical SADA Data at AACR; Omburtamab BLA Resubmitted; Reiterate Bu
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year-End 2021 Financials Reported; Modulating PT to $63
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA Moving Higher; Progress Across the Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Pre-BLA Meeting Done; Resubmission by End-1Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Resubmission Anticipated in 1Q22; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lutetium-Labeled Omburtamab Gets RPDD From FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oh DANYELZA, the Summer''s Gone But We See Sunshine
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D